There are currently 71 active clinical trials seeking participants for Triple Negative Breast Cancer research studies. The states with the highest number of trials for Triple Negative Breast Cancer participants are Texas, California, Florida and New York.
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT04282044
Recruiting
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovaria... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona +2 locations
Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Register for Updates
A Multicenter Cancer Biospecimen Collection Study
NCT04510129
Recruiting
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Curebase, San Francisco, California
Conditions: Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Colorectal Cancer
Register for Updates
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT03504488
Recruiting
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: University of Arizona Cancer Center, Tucson, Arizona +65 locations
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Register for Updates
Study of Screening Brain MRIs in Stage IV Breast Cancer
NCT05115474
Recruiting
The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Morton Plant Mease- Baycare, Clearwater, Florida +1 locations
Conditions: Triple Negative Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer
Register for Updates
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT05528133
Recruiting
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone receptor negative) breast cancer undergoing breast conservation therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Morton Plant Hospital - Baycare Health System, Clearwater, Florida +1 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT05746897
Recruiting
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: NEXT Oncology, Dallas, Dallas, Texas +1 locations
Conditions: Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
Register for Updates
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT05020860
Recruiting
The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Harris Health System - Smith Clinic, Houston, Texas +1 locations
Conditions: Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
Register for Updates
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
NCT03586297
Recruiting
The probability of pCR in TNBC patients receiving standard of care neoadjuvant chemotherapy treatment is associated with the dominance of specific intestinal and intratumoral microbiota that promote anti-tumor immunosurveillance.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/08/2024
Locations: Yale University - Yale Cancer Center, New Haven, Connecticut +2 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
NCT05645380
Recruiting
This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.
Gender:
Female
Ages:
Between 18 years and 70 years
Trial Updated:
12/05/2023
Locations: The University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas +6 locations
Conditions: Triple Negative Breast Cancer, Breast Cancer
Register for Updates
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT05868226
Recruiting
I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois +4 locations
Conditions: HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
Register for Updates
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT04837209
Recruiting
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: Dostarlimab Niraparib Radiation Therapy (RT), which is given per standard of care.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Sibley Memorial Hospital, Washington, District of Columbia +3 locations
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT04683679
Recruiting
The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radiation therapy alone).
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Register for Updates